學術活動
2025.10.12 | by 秘書處 秘書處
【請先報名】大腸直腸癌治療專題研討會
【請先報名】大腸直腸癌治療專題研討會
申請單位：高雄市胃腸道腫瘤關懷協會
時 間：114年10月12日（週日）12:00-14:30
地 點：高雄萬豪酒店
10 樓皇豪中餐廳
認定積分：本會醫師會員5分
備註：請事先報名(1130223@kmuh.org.tw)
Topic：Clinical utility of MRD testing and liquid biopsy (Lbx) in CRC
Liquid biopsy (Lbx) using circulating tumor DNA (ctDNA), which analyzes both gene alterations and tumor DNA burden, is advancing cancer management from early to late stages.
COSMOS-CRC-01 is a clinical trial evaluating molecular residual disease (MRD) across cancer types, including colorectal cancer, using Guardant Reveal, a tissue-free methylation-based assay interrogating >20,000 epigenomic regions. In an interim analysis, postoperative ctDNA positivity predicted poor outcomes, while longitudinal surveillance provided a 5.3-month lead time over imaging, with 81% sensitivity and >98% specificity, outperforming CEA.
The GOZILA study, a large Japanese multicenter trial, highlighted the power of liquid biopsy in advanced gastrointestinal cancers. Using Guardant360, a ctDNA-based assay that covers guideline-recommended biomarkers, the study demonstrated significantly higher success rates and faster turnaround times than tissue genotyping. The CHRONOS trial further underscored its value in resistance monitoring and anti-EGFR rechallenge. Building on this foundation, Guardant360 Liquid and the latest Guardant Infinity platform integrate genomic and epigenomic profiling, adding methylation-based tumor fraction (mTF) analysis, promoter methylation assessment, and accurate molecular tumor typing, thereby expanding the range of prognostic biomarkers.
Liquid biopsy provides powerful prognosis insights across both early and advanced CRC-informing recurrence risk and adjuvant therapy decisions in early disease, while enabling real-time monitoring of treatment response and resistance in advanced disease.
Topic: Optimized RAS WT Treatment Sequence and Future Treatment Trending in mCRC
The therapeutic landscape of metastatic colorectal cancer (mCRC) is rapidly evolving, with new emphasis on optimizing treatment strategies for patients harboring RAS wild-type (WT) tumors. This presentation will explore current evidence guiding the sequencing of targeted agents and chemotherapy to maximize efficacy, delay resistance, and preserve quality of life. Special focus will be placed on the integration of anti-EGFR therapy, emerging biomarkers, and their impact on first- and later-line choices. Furthermore, the talk will highlight recent trends in global practice, evolving clinical trial data, and future directions such as novel combinations and precision-driven sequencing. Together, these insights aim to refine decision-making and improve outcomes for patients with RAS WT mCRC in an era of personalized oncology.
Topic: Using ctDNA in Colorectal Cancer: Current and Evolving Practice in Patients with RAS Wild-Type-Insights from the PARADIGM phase 3 Study (Panitumumab)
Circulating tumor DNA (ctDNA) is transforming the management of colorectal cancer by enabling real-time molecular monitoring and guiding treatment decisions. In patients with RAS wild-type (WT) tumors, ctDNA offers a dynamic approach to detect emerging resistance, optimize sequencing, and refine personalized therapy strategies. This presentation will review the current and evolving clinical applications of ctDNA in metastatic colorectal cancer (mCRC), highlighting its integration with established treatment pathways. Insights from the phase 3 PARADIGM study of panitumumab will be discussed, including the role of ctDNA in confirming RAS WT status, predicting benefit, and informing treatment adaptation. Together, these data underscore ctDNA’s potential to shape precision oncology and improve outcomes for patients with RAS WT mCRC.
議程請自行下載
申請單位：高雄市胃腸道腫瘤關懷協會
時 間：114年10月12日（週日）12:00-14:30
地 點：高雄萬豪酒店
10 樓皇豪中餐廳
認定積分：本會醫師會員5分
備註：請事先報名(1130223@kmuh.org.tw)
Topic：Clinical utility of MRD testing and liquid biopsy (Lbx) in CRC
Liquid biopsy (Lbx) using circulating tumor DNA (ctDNA), which analyzes both gene alterations and tumor DNA burden, is advancing cancer management from early to late stages.
COSMOS-CRC-01 is a clinical trial evaluating molecular residual disease (MRD) across cancer types, including colorectal cancer, using Guardant Reveal, a tissue-free methylation-based assay interrogating >20,000 epigenomic regions. In an interim analysis, postoperative ctDNA positivity predicted poor outcomes, while longitudinal surveillance provided a 5.3-month lead time over imaging, with 81% sensitivity and >98% specificity, outperforming CEA.
The GOZILA study, a large Japanese multicenter trial, highlighted the power of liquid biopsy in advanced gastrointestinal cancers. Using Guardant360, a ctDNA-based assay that covers guideline-recommended biomarkers, the study demonstrated significantly higher success rates and faster turnaround times than tissue genotyping. The CHRONOS trial further underscored its value in resistance monitoring and anti-EGFR rechallenge. Building on this foundation, Guardant360 Liquid and the latest Guardant Infinity platform integrate genomic and epigenomic profiling, adding methylation-based tumor fraction (mTF) analysis, promoter methylation assessment, and accurate molecular tumor typing, thereby expanding the range of prognostic biomarkers.
Liquid biopsy provides powerful prognosis insights across both early and advanced CRC-informing recurrence risk and adjuvant therapy decisions in early disease, while enabling real-time monitoring of treatment response and resistance in advanced disease.
Topic: Optimized RAS WT Treatment Sequence and Future Treatment Trending in mCRC
The therapeutic landscape of metastatic colorectal cancer (mCRC) is rapidly evolving, with new emphasis on optimizing treatment strategies for patients harboring RAS wild-type (WT) tumors. This presentation will explore current evidence guiding the sequencing of targeted agents and chemotherapy to maximize efficacy, delay resistance, and preserve quality of life. Special focus will be placed on the integration of anti-EGFR therapy, emerging biomarkers, and their impact on first- and later-line choices. Furthermore, the talk will highlight recent trends in global practice, evolving clinical trial data, and future directions such as novel combinations and precision-driven sequencing. Together, these insights aim to refine decision-making and improve outcomes for patients with RAS WT mCRC in an era of personalized oncology.
Topic: Using ctDNA in Colorectal Cancer: Current and Evolving Practice in Patients with RAS Wild-Type-Insights from the PARADIGM phase 3 Study (Panitumumab)
Circulating tumor DNA (ctDNA) is transforming the management of colorectal cancer by enabling real-time molecular monitoring and guiding treatment decisions. In patients with RAS wild-type (WT) tumors, ctDNA offers a dynamic approach to detect emerging resistance, optimize sequencing, and refine personalized therapy strategies. This presentation will review the current and evolving clinical applications of ctDNA in metastatic colorectal cancer (mCRC), highlighting its integration with established treatment pathways. Insights from the phase 3 PARADIGM study of panitumumab will be discussed, including the role of ctDNA in confirming RAS WT status, predicting benefit, and informing treatment adaptation. Together, these data underscore ctDNA’s potential to shape precision oncology and improve outcomes for patients with RAS WT mCRC.
議程請自行下載
【附件下載】
TOP
學分查詢
線上報名
專科訓練
線上繳費